matt mindset ahead zbh result call lower
estim view previous note remedi
spend would constrain gross margin recent comment suggest
also spend retent invest specif
retent program note rel basi would dramat
differ would paid compens compani hit
plan last year expect deliv plan whatev end
creat headwind y/i cfo florin note would
sustain reinvest save tax reform growth invest area
think like pressur om consensu model coupl
fact anticip slow improv top line
number new product launch partial stemless shoulder
unlik would see materi revenu product
addit previous guid full suppli recent highlight
gener term situat like alway risk run
verif valid possibl timelin still hold think
unlik upsid given recent histori zbh hedg timelin
comment time expect new ceo bryan hanson take
advantag opportun set conserv guidanc earli tenur
understand provid guidanc call perhap guid
could give us better understand expens run rate much els
net-net think street number high lower number
pt account factor still like see near term challeng
think stock take time work expect improv
occur lower pt base ep
prior target base previou ep
quarterli annual ep usd
lower usd
return equiti ttm
link barclay live interact chart
consensu number thomson reuter
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight suppli improv expect
see better top line growth benefit
market-lead portfolio stabl sale forc
new product expect growth
improv help multipl expand
leverag increas
share gain help new product
commerci cost synergi upsid valuat
weak util affect core hip knee
market share loss core market price
pressur disrupt sale forc cost
competit continu suppli issu
haircut number expect slower recoveri
spend
believ mr hanson uniqu opportun reset expect street
number would prudent set conserv yet reason
level execut meet exceed consist mention think suppli
constraint lack new product boost mean slow improv
year greater improv
consensu current model revenu organ
lower estim organ compar prior
organ also model margin compress y/i
vs bp previous tweak tax assumpt model ep
vs prior con ep goe vs prior
con lower pt base ep
prior target base previou ep
guidanc uncertain believ longer term remain focus
growth current portfolio opportun reshap wamgr
portfolio manag remain ow would expect execut remedi
suppli disrupt growth improv new product launch lead signific
multipl expans stage think show-m stori expect
improv realli start
syk result hips/kne combin suggest slower expect
market growth rate expect head result syk hip/kne ww
growth xfx estim xfx acceler
sequenti y/i comp adjust basi off-set jnj weak
xfx jnj growth deceler sequenti y/i comp adjust basi
rememb impact hurrican would
expect acceler quarter given lose market share
suppli issu wont return full suppli least think unlik
improv comp adjust growth much sequenti
remind guidanc lower due suppli constraint
remind updat guidanc earn call expect
revenu rang xfx versu prior
xfx con guidanc includ bp acquisit ldr ep
expect rang versu prior con
fourth quarter expect revenu rang y/i
xfx vs con also expect ep fourth quarter vs con
y/i y/i growth y/i y/i growth y/i y/i growth y/i y/i growth y/i y/i growth y/i y/i growth y/i y/i y/i growth barclay zimmer biomet hold inc
compani report barclay research
guidanc assum market soft spill
assum similar product level progress non-affect brand help
put hand sale forc drive growth also pickup
assum persona partial knee term takedown ep
reduct due earn flow-through lower sale expect invest
special sale force/sal incent incur increas manufactur cost
neg impact gm throughout prior guid assum would
enter quarter healthier suppli situat comp-adjust
acceler organ compon takedown
off-set currenc ep takedown note organ
sale fx chang balanc due combin higher
product cost inventori charg tie north campu perform
would provid guidanc note gross margin profil
right way think gross margin next year
growthgross expens impli op bp improv qoqtax rate guidanc provid guidanc provid guidanc provid million lowmidpointhighno market soft growthreport product level progress no-affectedreport pickup persona partial fx takedown organ sale fxxfx ex-ldrhxfx ex-ldrh ex-bil dayseffect tax guidanc provid barclay
compani report barclay research
million except per share end dec last updat increas growth growth cash-flow ebitda profit ebit incom incom tax incom net average share ep cont increas cont op ex increas barclay zimmer biomet hold inc
matthew taylor cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli
relat specif recommend view express research report
